Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Cash from Financing Activities (2017 - 2025)

Selectis Health's Cash from Financing Activities history spans 14 years, with the latest figure at -$383707.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 60.59% year-over-year to -$383707.0; the TTM value through Sep 2025 reached -$1.0 million, down 125.81%, while the annual FY2024 figure was -$1.5 million, 148.42% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was -$383707.0 at Selectis Health, up from -$452881.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.1 million in Q4 2023 and bottomed at -$1.0 million in Q3 2023.
  • The 5-year median for Cash from Financing Activities is -$182439.0 (2025), against an average of -$179921.6.
  • The largest annual shift saw Cash from Financing Activities surged 1017.72% in 2021 before it plummeted 765.7% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$128705.0 in 2021, then plummeted by 519.61% to -$797467.0 in 2022, then skyrocketed by 236.62% to $1.1 million in 2023, then crashed by 99.76% to $2567.0 in 2024, then crashed by 15047.68% to -$383707.0 in 2025.
  • Per Business Quant, the three most recent readings for GBCS's Cash from Financing Activities are -$383707.0 (Q3 2025), -$452881.0 (Q2 2025), and -$182439.0 (Q1 2025).